AI-designed 'intrabodies' open new path for treating neurodegenerative diseases
University of Essex researchers use protein redesign to repurpose hundreds of antibodies for use inside human cells.
Researchers at the University of Essex have developed a method to create "intrabodies"—antibody fragments that function inside human cells—using AI-based protein redesign. This breakthrough allows for the direct targeting of toxic proteins linked to incurable neurodegenerative conditions, potentially bypassing a major hurdle in drug delivery.
According to findings published in Nature Communications on January 31, 2026, the team successfully converted 672 existing antibodies into stable intracellular versions. These intrabodies target proteins associated with Alzheimer’s, Parkinson’s, Huntington’s, and motor neurone disease (MND). The research, led by Dr. Caitlin O’Shea and Dr. Gareth Wright and funded by the MND Association, utilized redesign software developed by Nobel Prize winner David Baker and his group.
The Intracellular Barrier
Standard antibodies typically work only outside of cells, which presents a significant challenge for treating neurodegenerative diseases. These conditions often originate from the accumulation of toxic proteins deep within neurons, where traditional antibody-based drugs cannot reach. To overcome this, the Essex team identified that electrical charge is the critical factor determining whether antibody fragments remain stable and usable once they enter the intracellular environment.
By optimizing this charge through AI, the researchers ensured the fragments remained functional. "We’ve made intracellular antibodies that stick to proteins that cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s and motor neurone disease," said Dr. Gareth Wright.
Implications for Therapy
This development allows scientists to repurpose decades of existing antibody research for intracellular applications. By combining these AI-designed intrabodies with emerging gene therapy techniques, researchers may create new therapeutic strategies that hit specific molecular targets exactly where they originate within neurons.
Dr. Brian Dickie, Chief Scientist at the MND Association, noted that Wright and his colleagues have made a significant advance in overcoming one of the key challenges that has historically impeded the development of antibodies as treatments for diseases like MND.
Future Outlook
While the study provides a scalable method to repurpose millions of existing antibodies, the next phase involves integrating these fragments into viable delivery systems. The ability to stabilize these proteins inside the cell marks a shift toward more precise intracellular medicine. The transition from laboratory redesign to clinical treatment remains the primary objective for the research team, as they seek to move these AI-optimized tools from the bench to the bedside.